FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kite Pharma's Free Cash Flow for the
three
months ended in Jun. 2017 was $-38.10 Mil. Kite Pharma's Revenue for the
three
months ended in Jun. 2017 was $10.05 Mil. Therefore, Kite Pharma's FCF Margin % for the quarter that ended in Jun. 2017 was -379.01%.
The historical rank and industry rank for Kite Pharma's FCF Margin % or its related term are showing as below:
KITE'
s FCF Margin % Range Over the Past 10 Years
Min: -522.04 Med: 0 Max: 0
Current: -522.04
KITE's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -147.18
vs KITE: -522.04
Kite Pharma FCF Margin % Historical Data
The historical data trend for Kite Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kite Pharma's FCF Margin %
For the Biotechnology subindustry, Kite Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kite Pharma's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kite Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kite Pharma's FCF Margin % falls into.
Kite Pharma FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Kite Pharma's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kite Pharma FCF Margin % Related Terms
Thank you for viewing the detailed overview of Kite Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KITE has been successfully added to your 